EMA — authorised 16 July 2021
- Marketing authorisation holder: BAYER AG
- Status: approved
🇪🇺 Verquvo in European Union
EMA authorised Verquvo on 16 July 2021
Marketing authorisations
EMA — authorised 16 July 2021
- Application: EMEA/H/C/005319
- Marketing authorisation holder: Bayer AG
- Local brand name: Verquvo
- Indication: Treatment of symptomatic chronic heart failure
- Status: approved
Verquvo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in European Union
Frequently asked questions
Is Verquvo approved in European Union?
Yes. EMA authorised it on 16 July 2021; EMA authorised it on 16 July 2021.
Who is the marketing authorisation holder for Verquvo in European Union?
BAYER AG holds the EU marketing authorisation.